A Fulton County Superior Court judge denied granting a preliminary injunction against Inhibitex by a rival company, and Inhibitex said it would continue development of a new drug to fight infections in children.
Biosynexus, a Maryland-based company, had sought to stop further development of Veronate by Inhibitex, alleging use of Biosynexus trade secrets.
After a two-day hearing and ruling, Inhibitex said it told Biosynexus that it would seek to recover legal fees and costs if the suit was not dropped.
Veronate is currently in Phase II trials and has been given fast-track status by the FDA. It targets staphylococcal infections.
Inhibitex: www.inhibitex.com
